Physician profile
Neil R Soni
NPI 1306054150
$27,623.52
in general payments reported to CMS, 2019-2025
76 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 99% of Hospice and Palliative Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $171).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $4,294 · 2021: $5,152 · 2022: $3,342 · 2023: $4,568 · 2024: $5,363 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,588 · Food and Beverage: $5,528 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,587.50 |
| Food and Beverage | $5,528.36 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,033.02 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $3,771.48 | 2019-2022 | |
| Abbott Laboratories | $2,138.00 | 2019-2024 | Eterna, Proclaim |
| Boston Scientific Corporation | $886.61 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, Infinion 16 |
| Saluda Medical Americas, INC. | $880.77 | 2024-2025 | Evoke |
| Amgen INC. | $821.48 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Uswm, LLC | $808.33 | 2021-2024 | Lucemyra, Zimhi |
| Glaxosmithkline, LLC. | $667.57 | 2019-2025 | Trelegy Ellipta, Nucala |
| Collegium Pharmaceutical, INC. | $642.04 | 2020-2025 | Belbuca |
| Protega Pharmaceutials INC | $548.71 | 2025 | Roxybond |
| Pfizer INC. | $433.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $397.83 | 2019-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $396.64 | 2019-2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.10 | 2019-2025 | Relistor, Xifaxan |
| Medtronic, INC. | $276.54 | 2021 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.